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A B S T R A C T
Transient Epileptic Amnesia (TEA) is a subtype of temporal lobe epilepsy, typically presenting in a person's early
60s, and of unknown aetiology. Encephalitis caused by antibodies to NMDA receptors (NMDARE) has not pre-
viously been documented in TEA. We describe a 47-year-old male who satisfied criteria for TEA, but given his
atypical symptoms, was also screened for autoimmune epilepsy. High levels of serum NMDAR antibodies were
found, suggesting NMDARE. Immunosuppressive treatment gradually eliminated the NMDA receptor antibodies.
Our case extends the clinical spectrum associated with neuronal cell-surface autoantibodies to include atypical
cases of TEA.
1. Introduction
Transient Epileptic Amnesia (TEA) is a subtype of temporal lobe
epilepsy which typically presents in people aged in their early 60s. It is
characterised by repeated, brief (median 30min) episodes of mixed
anterograde and retrograde amnesia, often on awakening (Zeman and
Butler, 2010). One third of patients have exclusively amnestic attacks;
the remainder display additional manifestations of epilepsy (often ol-
factory hallucinations (Savage et al., 2017)). Interictal memory dis-
turbances also frequently arise, typically including accelerated long-
term forgetting (ALF) - the loss of normally acquired information over
hours to weeks; a patchy autobiographical amnesia; and impaired
memory for familiar routes and landmarks. The amnestic episodes re-
spond promptly to antiepileptic drugs (Butler et al., 2007). The syn-
drome is an important differential diagnosis of memory loss in mid- to
late-life.
Encephalitis caused by antibodies to NMDA receptors (NMDARE)
was first recognised in 2007 (Dalmau et al., 2007). It was initially de-
scribed primarily as a paraneoplastic disorder affecting young women
with ovarian teratomas, presenting dramatically with a ‘viral’ prodrome
followed by psychosis, cognitive dysfunction and seizures, often pro-
gressing to a distinctive movement disorder with dysautonomia and
coma. Since the original description, presentations have widened, in-
cluding cases with isolated psychosis, epilepsy or movement disorder,
predominant dysautonomia or hypoventilation, in men, women and
children, and mostly without a tumour (Irani et al., 2010). Structural
imaging is usually unremarkable but resting state connectivity has
shown bilateral hippocampal network dysfunction (Finke et al., 2013),
and indeed, the hippocampus has the highest density of NMDARs in the
human brain (Heine et al., 2015). Disease pathogenesis involves anti-
body-mediated internalisation of NMDARs with resulting NMDAR-hy-
pofunction. Current treatment involves the use of high-dose corticos-
teroids, plasma exchange and/or intravenous immunoglobulin as first-
line agents, plus rituximab, cyclophosphamide, as ‘add-on’ second-line
therapies in refractory cases. The roles of mycophenolate mofetil
(MMF) and azathioprine are poorly studied.
2. Case report
PT, a 47-year-old male shop-worker, presented in October 2012 at
age 44 with recurrent amnesia on awakening, characterised by dis-
orientation and repetitive questioning which would last for minutes, in
conjunction with 30 second ‘trance-like’ episodes during the day. As
reported by his partner, these daytime episodes were sometimes ac-
companied by repetitive swallowing movements, followed by dis-
orientation and repetitive questioning, and occurred in clusters of up to
seven per day. PT himself was aware of some but not all of these epi-
sodes, with partial recollection of being unable to remember. He did
report other memory changes, however, including an unexpectedly
rapid loss of newly acquired memories over days, and an unusual dif-
ficulty in recalling both autobiographical events from his adulthood and
familiar routes. Concurrently, PT developed olfactory hallucinations;
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uncharacteristic headaches with migrainous features; postural arm
tremor, tingling legs, malaise and low mood. The olfactory hallucina-
tions, which reminded him of candy floss, occurred independently of
the amnestic episodes and could last for up to a day. He also reported
some subjective blunting of his sense of smell. His medical history was
unremarkable, aside from symptoms of depression during the previous
year and a remote history of heavy alcohol use.
A timeline of PT's symptoms and investigations is provided in
Table 1. Initial brain MRI showed subtly increased T2 signal in the right
hippocampus, in the absence of any recent episodes. EEG was normal.
Clinical examination revealed no focal neurological signs. Following an
initial clinical diagnosis of TEA, PT was treated with lamotrigine
(commencing at 25mg and increasing incrementally up to 100mg
twice a day), resolving his trance-like and amnestic attacks, but not his
other symptoms (namely headaches, tingling sensation in the limbs,
and olfactory hallucinations).
Although PT satisfied criteria for a diagnosis of TEA, in view of his
relatively young age for a diagnosis of TEA, varied neurological
symptoms and subtle MRI changes, the possibility of an autoimmune
epilepsy was raised. Screening for associated antibodies revealed high
levels of serum NMDAR antibodies (strong binding persisted at a dilu-
tion of 1:500, live cell based assay and rodent brain im-
munohistochemistry). LGI1, CASPR2, GABA(B)R- and AMPAR-anti-
bodies were negative. CT scan of thorax, abdomen and pelvis and
testicular ultrasound showed no evidence of malignancy. CSF NMDAR-
antibodies (now recommended to support this diagnosis) were not
measured, but the combination of amnesia, mood disturbance, seizures,
a movement disorder, imaging findings and high serum NMDAR anti-
bodies made a diagnosis of NMDARE likely.
Initial treatment with intravenous methylprednisolone followed by
oral maintenance therapy for 6months led to partial resolution of
symptoms, with a lower NMDAR-antibody level (1:100). Further
treatment with plasma exchange followed by maintenance therapy with
MMF and oral steroids substantially improved his symptoms and
eliminated serum NMDA-receptor antibodies. Seven months later, re-
lapsing symptoms were associated with the reappearance of the
NMDAR-antibodies and a further course of intravenous methylpredni-
solone and plasma exchange was given. Repeat MRI now appeared
normal (see Fig. 1a). PT is currently well on maintenance MMF, la-
motrigine and a reducing dose of prednisolone.
Neuropsychological assessment was conducted in 2013 and 2015
using standard measures of: general cognitive ability (Wechsler
Abbreviated Scale of Intelligence and Addenbrooke's Cognitive
Examination-Revised – ACE-R), anterograde memory (Anna Thompson
story from Wechsler Memory Scale 3rd edition, Rey Complex Figure
Test), and executive function (verbal fluency tasks). Additional memory
testing in 2015 included research measures of ALF (based on a modified
administration of the Rey Auditory Verbal Learning test) and a mod-
ified Autobiographical Memory Interview (Zeman and Butler, 2010).
Results for both 2013 and 2015 assessments indicated preserved gen-
eral ability (estimated IQ=109), with stable and preserved visuospa-
tial skills, verbal and non-verbal reasoning, verbal generativity and
Table 1
Clinical timeline of symptoms and investigations.
Timeline Event
Oct 2012 Onset of amnestic episodes, trance-like episodes and physical symptoms
May-June 2013 Lamotrigine commenced; amnestic seizures ceased; EEG (normal); MRI (subtle changes)
July-August 2013 One further amnestic seizure; NMDA positive (1:500); CT (normal); neuropsychological assessment (i) conducted
Sept-Oct 2013 Lamotrigine dose increased; no further seizures; intravenous steroids introduced plus 6-month oral maintenance therapy
Feb-March 2014 Partial improvement: NMDA positive (1:100), but headaches, olfactory hallucinations, numb fingers return
Mar-April 2014 Plasma exchange initiated plus steroids and mycophenolate - > substantial improvements in symptoms; NMDA negative
Oct-Nov 2014 Physical symptoms heightened (headache, pain); NMDA positive(1:100); 2nd course plasma exchange plus intravenous steroids provided
Jan-April 2015 Physical symptoms improve; NMDA negative
June-Aug 2015 MRI (normal); NMDA negative; some headaches; neuropsychological assessment (ii) conducted
Oct 2015-Mar 2016 Reported improvement in memory; no reported physical symptoms; NMDA negative
Fig. 1. A) MRI showed subtle increase in
signal in the right hippocampus in June
2013 which was no longer detectable in
June 2015; B) Neuropsychological testing
(2015) shows that PT can acquire new
verbal information normally, but recall is
significantly lower than n=10 healthy
controls (HC) after a 30-minute delay
(Crawford's modified t-test: p= .024), with
further reductions at one week (< 30% re-
tained) in comparison to healthy controls
(where the average is more than double PT's
score, p= .05). Likewise, PT's ability to re-
call rich, episodic details of events from
different decades of his life is also sub-
stantially poorer than healthy controls
(p= .001).
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retention of verbal material (stories) at 30-minute delay. Recall of vi-
sual information, however, was poor at both assessments. While initial
encoding of information appeared to have worsened in 2015, PT now
showed benefit from repeated exposure of material (e.g. in learning a
name and address on the ACE-R). Further memory testing completed at
the second assessment to evaluate accelerated long-term forgetting and
autobiographical amnesia, indicated mild decrements in memory at
standard delays, with evidence suggestive of accelerated forgetting
after a 1-week delay, and pronounced autobiographical amnesia when
comparing PT with 10 healthy older but IQ-matched controls (mean
age= 59, IQ= 115) (Fig. 1b).
3. Discussion
The aetiology of TEA is unknown in most cases. There is no evidence
for an elevated cerebrovascular disease burden, and the condition is not
generally a precursor of dementia (Savage et al., 2016). While ALF and
autobiographical amnesia have been described in paraneoplastic and
autoimmune forms of limbic encephalitis (Witt et al., 2015), this is the
first report which clearly documents TEA in the context of an auto-
immune epilepsy. Our case further extends the widening clinical spec-
trum associated with neuronal cell-surface autoantibodies, indicating
that autoimmunity should be considered not only when features spe-
cifically suggest an auto-immune aetiology, but also in cases where
features are atypical for alternative diagnoses (such as relatively young
age in TEA). It would be of interest in future work to assay CSF NMDAR-
autoantibodies.
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